Biologics and Biosimilars

Biologics are medicines made from living cells through highly complex manufacturing processes. A biosimilar product is a biologic product that is approved based on demonstrating that it is highly similar to an FDA‐approved biologic product. Biologics, on the other hand, are much more complex molecules (in fact, they are proteins) created through biological processes in living cells. Indeed, the demand for biologics is growing exponentially due to their ability to bind to specific cells, which means they have fewer side effects than broadly acting drugs. The chemicals traditionally used in cancer therapy, for instance, bind to every fast-dividing cell because this is a hallmark of cancer cells, but this results in observed side effects such as hair loss. Biologics are better at targeting cancerous cells.

  • Biologics as protein therapies
  • Biosimilar labeling
  • Analytical characterization

Related Conference of Biologics and Biosimilars

February 25-26, 2026

16th International Conference on Chemistry Meeting

Paris, France
February 26-27, 2026

29th World Congress on Materials Chemistry

Paris, France
June 17-18, 2026

15th World Congress on Chromatography

Paris, France
August 11-12, 2026

5th World Congress on Plasma Chemistry and Plasma Processing

Amsterdam, Netherlands
September 14-15, 2026

22nd European Organic Chemistry Congress

Rome, Italy
September 21-22, 2026

16th International Chemistry Congress

Barcelona, Spain
November 26-27, 2026

6th International Conference on Petrochemistry and Natural Gas

Amsterdam, Netherlands

Biologics and Biosimilars Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in